IL1R2 and COVID-19: IL-1R2 upregulation and release in soluble form are observed in several inflammatory diseases in patients, including critically ill patients with sepsis, acute meningococcal infection, trauma, necrotizing enterocolitis in preterm infants, and acute respiratory distress syndrome, such as COVID-19, and are correlated with the severity of the disease [69–72].